Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 9 September 1983:
Vol. 221. no. 4615, pp. 1054 - 1057
DOI: 10.1126/science.6136093
Prev | Table of Contents | Next

Articles

Science, Vol 221, Issue 4615, 1054-1057
Copyright © 1983 by American Association for the Advancement of Science

articles

Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons

FJ White and RY Wang

Prolonged treatment with classical antipsychotic drugs decreased the number of spontaneously active dopamine neurons in both the substantia nigra (A9) and the ventral tegmental area (A10) of the rat brain. In contrast, treatment with atypical antipsychotic drugs selectively decreased the number of A10 dopamine neurons. Related drugs lacking antipsychotic efficacy failed to decrease dopamine activity. These findings suggest that the inability of atypical antipsychotic drugs to decrease A9 dopamine neuronal activity may be related to their lower potential for causing tardive dyskinesia and that the inactivation of A10 neurons may be involved in the delayed onset of therapeutic effects during treatment.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour.
L Dahan, H Husum, O Mnie-Filali, J Arnt, P Hertel, and N Haddjeri (2009)
J Psychopharmacol 23, 177-189
   Abstract »    PDF »
Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection.
J. A. Lieberman, F. P. Bymaster, H. Y. Meltzer, A. Y. Deutch, G. E. Duncan, C. E. Marx, J. R. Aprille, D. S. Dwyer, X.-M. Li, S. P. Mahadik, et al. (2008)
Pharmacol. Rev. 60, 358-403
   Abstract »    Full Text »    PDF »
Ether-a-go-go Related Gene Potassium Channels: What's All the Buzz About?.
P. D. Shepard, C. C. Canavier, and E. S. Levitan (2007)
Schizophr Bull 33, 1263-1269
   Abstract »    Full Text »    PDF »
WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Preclinical Antipsychotic-Like Activity.
K. L. Marquis, A. L. Sabb, S. F. Logue, J. A. Brennan, M. J. Piesla, T. A. Comery, S. M. Grauer, C. R. Ashby Jr., H. Q. Nguyen, L. A. Dawson, et al. (2007)
J. Pharmacol. Exp. Ther. 320, 486-496
   Abstract »    Full Text »    PDF »
Postnatal Inorganic Lead Exposure Reduces Midbrain Dopaminergic Impulse Flow and Decreases Dopamine D1 Receptor Sensitivity in Nucleus Accumbens Neurons.
M. Tavakoli-Nezhad and D. K. Pitts (2005)
J. Pharmacol. Exp. Ther. 312, 1280-1288
   Abstract »    Full Text »    PDF »
Long-Term K+ Channel-Mediated Dampening of Dopamine Neuron Excitability by the Antipsychotic Drug Haloperidol.
J. Hahn, T. E. Tse, and E. S. Levitan (2003)
J. Neurosci. 23, 10859-10866
   Abstract »    Full Text »    PDF »
Serotonin Reduces the Hyperpolarization-Activated Current (Ih) in Ventral Tegmental Area Dopamine Neurons: Involvement of 5-HT2 Receptors and Protein Kinase C.
Z. Liu, E. B. Bunney, S. B. Appel, and M. S. Brodie (2003)
J Neurophysiol 90, 3201-3212
   Abstract »    Full Text »    PDF »
Glutamatergic Afferents from the Hippocampus to the Nucleus Accumbens Regulate Activity of Ventral Tegmental Area Dopamine Neurons.
S. B. Floresco, C. L. Todd, and A. A. Grace (2001)
J. Neurosci. 21, 4915-4922
   Abstract »    Full Text »    PDF »
Ventral Tegmental Area Afferents to the Prefrontal Cortex Maintain Membrane Potential 'Up' States in Pyramidal Neurons via D1 Dopamine Receptors.
B. L. Lewis and P. O'Donnell (2000)
Cereb Cortex 10, 1168-1175
   Abstract »    Full Text »    PDF »
Acute and Chronic Administration of the Selective D3 Receptor Antagonist SB-277011-A Alters Activity of Midbrain Dopamine Neurons in Rats: An In Vivo Electrophysiological Study.
C. R. Ashby Jr., Y. Minabe, G. Stemp, J. J. Hagan, and D. N. Middlemiss (2000)
J. Pharmacol. Exp. Ther. 294, 1166-1174
   Abstract »    Full Text »
Striatal Nitric Oxide Signaling Regulates the Neuronal Activity of Midbrain Dopamine Neurons In Vivo.
A. R. West and A. A. Grace (2000)
J Neurophysiol 83, 1796-1808
   Abstract »    Full Text »    PDF »
Behavioral Evidence of Depolarization Block of Dopamine Neurons after Chronic Treatment with Haloperidol and Clozapine.
S. M. Boye and P.-P. Rompre (2000)
J. Neurosci. 20, 1229-1239
   Abstract »    Full Text »    PDF »
Clozapine, But Not Haloperidol, Prevents the Functional Hyperactivity of N-Methyl-D-Aspartate Receptors in Rat Cortical Neurons Induced by Subchronic Administration of Phencyclidine.
V. L. Arvanov and R. Y. Wang (1999)
J. Pharmacol. Exp. Ther. 289, 1000-1006
   Abstract »    Full Text »
Dopamine receptors, antipsychotic action and schizophrenia.
G. P. Reynolds (1999)
J Psychopharmacol 13, 202-203
   PDF »
Effects of Acute and Repeated Administration of Amisulpride, a Dopamine D2/D3 Receptor Antagonist, on the Electrical Activity of Midbrain Dopaminergic Neurons.
G. Di Giovanni, M. Di Mascio, V. Di Matteo, and E. Esposito (1998)
J. Pharmacol. Exp. Ther. 287, 51-57
   Abstract »    Full Text »
Selective Action of Acute Systemic Clozapine on Acetylcholine Release in the Rat Prefrontal Cortex by Reference to the Nucleus Accumbens and Striatum.
M. A. Parada, L. Hernandez, M. P. De Parada, P. Rada, and E. Murzi (1997)
J. Pharmacol. Exp. Ther. 281, 582-588
   Abstract »    Full Text »
Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer Disease.
N. C. Bodick, W. W. Offen, A. I. Levey, N. R. Cutler, S. G. Gauthier, A. Satlin, H. E. Shannon, G. D. Tollefson, K. Rasmussen, F. P. Bymaster, et al. (1997)
Arch Neurol 54, 465-473
   Abstract »    PDF »
Dopamine Receptor Subtypes: Differential Regulation after 8 Months Treatment with Antipsychotic Drugs.
W. J. Florijn, F. I. Tarazi, and I. Creese (1997)
J. Pharmacol. Exp. Ther. 280, 561-569
   Abstract »    Full Text »
What is an atypical antipsychotic?.
G. P. Reynolds (1997)
J Psychopharmacol 11, 195-199
   Abstract »    PDF »
Striatal D2 Dopamine Receptor Characteristics in Neuroleptic-Naive Schizophrenic Patients Studied With Positron Emission Tomography.
J. Hietala, E. Syvalahti, K. Vuorio, K. Nagren, P. Lehikoinen, U. Ruotsalainen, V. RakkOlainen, V. Lehtinen, and U. Wegelius (1994)
Arch Gen Psychiatry 51, 116-123
   Abstract »    PDF »
Effects of Metabolic Perturbation on Plasma Homovanillic Acid in Schizophrenia: Relationship to Prefrontal Cortex Volume.
A. Breier, O. R. Davis, R. W. Buchanan, L. A. Moricle, and R. C. Munson (1993)
Arch Gen Psychiatry 50, 541-550
   Abstract »    PDF »
Clinical and Biologic Response to Clozapine in Patients With Schizophrenia: Crossover Comparison With Fluphenazine.
D. Pickar, R. R. Owen, R. E. Litman, P. E. Konicki, R. Gutierrez, and M. H. Rapaport (1992)
Arch Gen Psychiatry 49, 345-353
   Abstract »    PDF »
Is it possible to model psychotic states in animals?.
S. D. Iversen (1987)
J Psychopharmacol 1, 154-176
   PDF »
Longitudinal Measurement of Plasma Homovanillic Acid Levels in Schizophrenic Patients: Correlation With Psychosis and Response to Neuroleptic Treatment.
D. Pickar, R. Labarca, A. R. Doran, O. M. Wolkowitz, A. Roy, A. Breier, M. Linnoila, and S. M. Paul (1986)
Arch Gen Psychiatry 43, 669-676
   Abstract »    PDF »
Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients.
D Pickar, R Labarca, M Linnoila, A Roy, D Hommer, D Everett, and S. Paul (1984)
Science 225, 954-957
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)